Keywords: Apo; apolipoprotein; AA; African American; BMI; body mass index; CRP; high sensitivity c-reactive protein; CVD; cardiovascular disease; EA; European American; GLM; generalized linear modeling; HDL-C; serum HDL cholesterol; HDL-P; plasma HDL particles; LDL
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Lipoproteins; Cardiovascular disease prevention; Comparative effectiveness; Health services research; Outcomes; Risk factors; CHD; coronary heart disease; LDL-C; low-density lipoprotein cholesterol; LDL-P; low-density lipoprotein particle number; MESA; mu
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Improvement of the omega 3 index of healthy subjects does not alter the effects of dietary saturated fats or n-6PUFA on LDL profiles
Keywords: Lipids; Omega-3 polyunsaturated fatty acids; Saturated fatty acids; Nuclear magnetic resonance spectroscopy; Lipoprotein profiles; 18:2n-6; linoleic acid; 22:6n-3; docosahexaenoic acid; 20:5n-3; eicosapentaenoic acid; BMI; body mass index; CVD; cardiovasc
The association between N-terminal pro B-type natriuretic peptide and lipoprotein particle concentration plateaus at higher N-terminal pro B-type natriuretic peptide values: Multi-Ethnic Study on Atherosclerosis
Keywords: BNP; B-type Natriuretic Peptide; CVD; Cardiovascular Disease; CHD; Coronary Heart Disease; NT-proBNP; Amino Terminal B-type Natriuretic Peptide; LDL-P; Low Density Lipoprotein Particle; HDL-P; High Density Lipoprotein Particle; IDL-P; Intermediate Density
HDL particle number measured on the Vantera®, the first clinical NMR analyzer
Keywords: NMR; nuclear magnetic resonance; HDL; high-density lipoprotein; HDL-P; HDL particle number; HDL; high-density lipoprotein; CVD; cardiovascular disease; HDL-C; high-density lipoprotein-cholesterol; LDL-C; low-density lipoprotein-cholesterol; VLDL; very
Laboratory validation of a low density lipoprotein apolipoprotein-B assay
Keywords: Apo-B; apolipoprotein B; LDL; low density lipoprotein; LDL-C; low density lipoprotein cholesterol; LDL-P; low density lipoprotein particle number; VLDL; very low density lipoprotein; IDL; intermediate density lipoprotein; Lp(a); lipoprotein (a); CHD; coro
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study
Keywords: Cholesterol; Hypercholesterolemia; Hyperlipoproteinemia; Lipoprotein; LDL particle; LDL-P; Statin;
NMR measurement of LDL particle number using the Vantera® Clinical Analyzer
Keywords: NMR; Nuclear magnetic resonance; LDL-P; Low density lipoprotein particle number; LDL-C; Low density lipoprotein-cholesterol; CLSI; Clinical Laboratory Standards Institute; CV; Coefficient of variation; CVD; Cardiovascular disease; LDL; Low density lipopro
Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: A cost-effectiveness analysis
Keywords: Cost of drug therapy; Cost-effectiveness analysis; Cost-utility analysis; Lipoprotein; LDL-P; Statin therapy
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
Keywords: LDL-C; LDL-P; Statin therapy
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
Keywords: [3H]-PAF; platelet activating factor; DIACOR; Diabetes and Combined Lipid Therapy Regimen; FIELD; Fenofibrate Intervention and Event Lowering in Diabetes; HDL-C; high-density lipoprotein cholesterol; HRP; horseradish-peroxidase; ICAM-1; intercellular adhe